✦ LIBER ✦

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

✍ Scribed by Silvia La Monica; Maricla Galetti; Roberta R. Alfieri; Andrea Cavazzoni; Andrea Ardizzoni; Marcello Tiseo; Marzia Capelletti; Matteo Goldoni; Sara Tagliaferri; Antonio Mutti; Claudia Fumarola; Mara Bonelli; Daniele Generali; Pier Giorgio Petronini

Book ID: 113488820
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 534 KB
Volume: 78
Category: Article
ISSN: 0006-2952
DOI: 10.1016/j.bcp.2009.04.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Marsdenia tenacissima extract restored g

Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells

✍ Han, Shu-Yan; Zhao, Ming-Bo; Zhuang, Gui-Bao; Li, Ping-Ping 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 996 KB

Everolimus synergizes with gefitinib in

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

✍ Dong, Song; Zhang, Xu-Chao; Cheng, Hua; Zhu, Jian-Quan; Chen, Zhi-Hong; Zhang, Y 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 753 KB

Functional characterization of gefitinib

Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines

✍ Maricla Galetti; Roberta R. Alfieri; Andrea Cavazzoni; Silvia La Monica; Mara Bo 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 404 KB

Suppression of Stat3 activity sensitizes

Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells

✍ Huan-Chih Chiu; Ding-Li Chou; Chin-Ting Huang; Wen-Hsing Lin; Tzu-Wen Lien; Kuei 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 768 KB

Establishment of a human non-small cell

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib

✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m

Gefitinib in advanced non-small cell lun

Gefitinib in advanced non-small cell lung cancer

✍ R. Sharma; M. Boyer; S. Clarke; M. Millward 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB